Literature DB >> 30476026

Echo-derived peak cardiac power output-to-left ventricular mass with cardiopulmonary exercise testing predicts outcome in patients with heart failure and depressed systolic function.

Nicola Riccardo Pugliese1, Iacopo Fabiani1, Giulia Elena Mandoli1, Giacinta Guarini1, Gian Giacomo Galeotti1, Mario Miccoli2, Alberto Lombardo1, Anca Simioniuc1, Giovanni Bigalli1, Roberto Pedrinelli1, Frank L Dini1.   

Abstract

AIMS: Peak cardiac power output-to-mass (CPOM) represents a measure of the rate at which cardiac work is delivered respect to the potential energy stored in left ventricular (LV) mass. We studied the value of CPOM and cardiopulmonary exercise test (CPET) in risk stratification of patients with heart failure (HF). MATERIALS AND
RESULTS: We studied 159 patients with chronic HF (mean rest LV ejection fraction 30%) undergoing CPET and exercise stress echocardiography. CPOM was calculated as the product of a constant (K = 2.22 × 10-1) with cardiac output (CO) and the mean blood pressure (MBP), divided by LV mass (M), and expressed in the unit of W/100 g: CPOM = [K × CO (L/min) × MBP (mmHg)]/LVM(g). Patients were followed-up for the primary endpoint, including all-cause death, ventricular assist device implantation, and heart transplantation, and the secondary endpoint that comprised hospitalization for HF. In multivariate Cox regression analyses, peak CPOM was selected as the most powerful independent predictor of both primary and secondary endpoint [hazard ratio (HR) 0.004, 95% confidence interval (CI) 0.004-0.3; P = 0.002 and HR 0.09, 95% CI 0.02-0.55; P = 0.009]. Sixty-month survival free from the combined endpoint was 85% in those exhibiting oxygen consumption (VO2) > 14 mL/min/kg and peak CPOM > 0.6 W/100 g. Peak VO2 ≤ 14 mL/min/kg provided incremental prognostic value over demographic and clinical variables, brain natriuretic peptide, and resting echocardiographic parameters (χ2 from 58 to 64; P = 0.04), that was further increased by peak CPOM ≤ 0.6 W/100 g (χ2 77; P < 0.001).
CONCLUSION: Peak CPOM and peak VO2 showed independent and incremental prognostic values in patients with chronic HF. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cardiac work; cardiopulmonary exercise test; exercise stress echocardiography; heart failure; prognosis

Year:  2019        PMID: 30476026     DOI: 10.1093/ehjci/jey172

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  5 in total

1.  Resting Cardiac Power Predicts Adverse Outcome in Heart Failure Patients With Preserved Ejection Fraction: A Prospective Study.

Authors:  Shiqi Wang; Aiqi Chen; Xiaokai Duan
Journal:  Front Cardiovasc Med       Date:  2022-07-05

2.  Overcoming the Limits of Ejection Fraction and Ventricular-Arterial Coupling in Heart Failure.

Authors:  Elena-Laura Antohi; Ovidiu Chioncel; Serban Mihaileanu
Journal:  Front Cardiovasc Med       Date:  2022-01-21

3.  Prognostic significance of resting cardiac power to left ventricular mass and E/e' ratio in heart failure with preserved ejection fraction.

Authors:  Cong Chen; Jie Zhao; Ruicong Xue; Xiao Liu; Wengen Zhu; Min Ye
Journal:  Front Cardiovasc Med       Date:  2022-08-18

Review 4.  Arterial Hypertension and Cardiopulmonary Function: The Value of a Combined Cardiopulmonary and Echocardiography Stress Test.

Authors:  Lavinia Del Punta; Nicolò De Biase; Nicola Riccardo Pugliese; Stefano Masi; Alessio Balletti; Francesco Filidei; Alessandra Pieroni; Silvia Armenia; Alessandro Mengozzi; Matteo Mazzola; Valerio Di Fiore; Frank Lloyd Dini; Javier Rosada; Agostino Virdis; Stefano Taddei
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-02-02

5.  Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes.

Authors:  Lorenzo Nesti; Nicola Riccardo Pugliese; Paolo Sciuto; Nicolò De Biase; Matteo Mazzola; Iacopo Fabiani; Domenico Trico; Stefano Masi; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2021-06-22       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.